The raised guidance and strong operational momentum across both segments support a positive outlook. Monitor STELARA erosion trajectory and the new supply chain restructuring costs. The stock may see modest upside as the beat was small but guidance raise confirms underlying strength.
Drugs in focus
JNJ drug pipeline →DARZALEX
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- Time to market
- Already approved and on the market — DARZALEX (IV) since Nov 2015 and DARZALEX FASPRO (subcutaneous) since May 2020; label expansion for newly diagnosed multiple myeloma added ~Jan 2026.
- Next catalyst
- None dated
What to watchFor JNJ shareholders, DARZALEX is a cash-cow growth driver, not a binary, treat it as part of the Innovative Medicine growth story (with CARVYKTI, TREMFYA, SPRAVATO) that supported the FY2026 guidance raise, and watch each Genmab 6-K for quarterly DARZALEX net sales as the cleanest read on the franchise. The bigger near-term event to track is competitive: Bristol Myers' iberdomide + daratumumab + dexamethasone PDUFA landed Aug 17, 2026, and BMY's bb2121 CAR-T Phase 3 readout is pending.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA Named in filing
- ● SPRAVATO 4/10 Approved Named in filing
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co Named in filing
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies Named in filing
- ● EDURANT 3/10 Approved / marketed Named in filing
- 11 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 15 $247.02entry
- T+1 · 4mo ago +1.19%α +1.74% · $249.97
- T+5 · 4mo ago +3.49%α +4.47% · $255.63
- T+20 · 3mo ago +5.59%α +3.25% · $260.84
- T+60 · 6w ago +3.83%α +1.30% · $256.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
JNJ reported Q2 2026 adjusted EPS of $2.90, a 1.6% beat vs. consensus of $2.85, on revenue of $25.31B (6.6% YoY growth, slightly above $25.06B consensus). The company raised its full-year 2026 adjusted EPS guidance by $0.13 to $11.68 at the midpoint (8.2% YoY growth) and raised its reported sales guidance to $101.1B at the midpoint (7.3% YoY growth). Strong performance was driven by Innovative Medicine (DARZALEX, CARVYKTI, TREMFYA, SPRAVATO) and MedTech (Cardiovascular, Surgery), partially offset by STELARA erosion from biosimilar competition.
Key Financial Metrics
Key Facts
- Q2 2026 reported sales of $25.31B, up 6.6% YoY, with operational growth of 5.6% and adjusted operational growth of 5.7%
- Adjusted EPS of $2.90 beat consensus of $2.85 by 1.6%
- Full-year 2026 adjusted EPS guidance raised by $0.13 to $11.68 midpoint (8.2% YoY growth)
- Full-year 2026 reported sales guidance raised to $101.1B midpoint (7.3% YoY growth)
- Innovative Medicine sales grew 7.8% reported (6.8% operational), driven by DARZALEX (+18.9%), CARVYKTI (+49.4%), TREMFYA (+72.5%), SPRAVATO (+40.8%), and CAPLYTA (+70.9%)
- MedTech sales grew 4.5% reported (3.6% operational), led by Cardiovascular (+4.0%) and Surgery (+3.9%)
- STELARA declined 55.2% YoY due to biosimilar competition, an approximate 760 bps drag on Innovative Medicine growth
- Free cash flow (YTD) estimated at $8.7B vs $6.2B in prior year period
- New supply chain restructuring program initiated in Innovative Medicine with estimated costs of $650-$750M through FY2029
Financial Impact
Q2 revenue $25.31B (+6.6% YoY), adjusted EPS $2.90 (+4.7% YoY); FY2026 guidance raised to $101.1B sales and $11.68 adjusted EPS at midpoints
Risk Factors
- STELARA biosimilar erosion continues to pressure Immunology segment (55.2% decline in Q2)
- New supply chain restructuring program adds $650-$750M in costs through FY2029
- Litigation-related adjustments of $267M in Q2 remain a recurring headwind
- MedTech growth of 3.6% operational is below the overall company rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000200406-26-000146 |
| Document: a2026q2exhibit991.htm | 0000200406-26-000146 |
| Document: jnj-20260715.htm | 0000200406-26-000146 |
| Document: 0000200406-26-000146-index-headers.html | 0000200406-26-000146 |
| Document: 0000200406-26-000146-index.html | 0000200406-26-000146 |
| Document: 0000200406-26-000146.txt | 0000200406-26-000146 |
| 8-K Data (Synthetic) | 0000200406-26-000146 |
Track record
21 reports on JNJ
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers